Complete loss of SLC30A8 in humans improves glucose metabolism and beta cell function
Lamarche, L. B.; Koch, C.; Khalid, S.; Zaman, M.; Zessis, R.; Clement, M. E.; Denning, D. P.; Goldfine, A. B.; Abbasi, A.; Harrow, J. L.; Underwood, C.; Tsunoyama, K.; Asaumi, M.; Kou, I.; Rodriguez-Flores, J. L.; Shuldiner, A. R.; Rasheed, A.; Jahanzaib, M.; Mian, M. R.; Liaqat, M. B.; Abdulsalam, U.; Sultana, R.; Jalal, A.; Saeed, M. H.; Abbas, S.; Memon, F. R.; Ishaq, M.; Gurtan, A. M.; Dominy, J. E.; Saleheen, D.
Show abstract
Genetic association studies have demonstrated that partial loss of SLC30A8 function protects against type 2 diabetes (T2D) in humans, but the impact of complete loss of SLC30A8 function remains unknown. From whole-exome and genome sequencing of 100,814 participants in the Pakistan Genome Resource, we identified fifteen SLC30A8 knockouts, including homozygotes for a variant enriched in South Asians (Gln174Ter) and 615 heterozygotes for loss-of-function (LoF) variants. T2D risk was lower in SLC30A8 LoF hetero- and homozygotes, and the protective effect strengthens in a gene dose-dependent manner (ORadditive=0.63 [0.53-0.78, p=7.5E-07], ORrecessive=0.27 [0.09-0.80, p=0.018]). Recall-by-genotype of SLC30A8 LoF hetero- and homozygotes and their family members with oral glucose tolerance tests showed a gene dose-dependent reduction in glucose levels coupled with elevated insulin. Corrected Insulin Response, Disposition Index, and Insulin Sensitivity Index in LoF hetero- and homozygotes indicated higher glucose-stimulated insulin secretion with preserved beta cell function. These data suggest that therapeutic knockdown of SLC30A8, up to and including complete knockout, may treat T2D safely and effectively.
Matching journals
The top 8 journals account for 50% of the predicted probability mass.